COVID-19 Pandemic
Applications received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.
On this page you’ll find answers to frequently asked questions about mRNA vaccines.
All about the vaccines - briefly and concisely explained
Vaccines: Rapid solution for new diseases?
Swismedic - The way a vaccination works
How an mRNA vaccine works
How a vector vaccine works?
How a protein vaccine works
How is the safety of vaccines monitored?
Communication regarding COVID-19
01.06.2023
Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3
11.04.2023
Bivalent Original / Omicron BA.4-5 mRNA vaccine (tozinameran / famtozinameran) approved
27.03.2023
Three formulations (authorisation nos. 68225 and 68710, with 30 and 10 μg/dose) authorised for five years
08.03.2023
Spikevax bivalent Original / Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over
24.02.2023
16,855 reports of suspected adverse vaccination reactions evaluated
23.01.2023
Update of the validity period of EMA GMP certificates
25.11.2022
16,212 reports of suspected adverse vaccination reactions evaluated
18.11.2022
Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222)
04.11.2022
Results from laboratory analyses now available
